SANTA MONICA, Calif. and LAS VEGAS, July 9 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has signed a lease for a 17,000 square foot building in Las Vegas, Nevada, for a state-of-the-art laboratory for the storage of multiple stem cell products including umbilical cord blood stem cells.
"This will be the largest stem cell laboratory and cryogenic storage facility in Nevada and one of the largest in the U.S.," said Company founder and CEO Matthew Schissler. "The lab will first be used to process and store umbilical cord blood stem cells, with a target date to start processing in the fourth quarter of 2009. In 2010, CBAI intends to expand its cryogenic storage services to other forms of stem cells, including peripheral blood stem cell and adipose tissues."
The new state-of-the-art lab will be built out in the Spencer Airport Business Park at 1857 Helm Drive. "CorCell, the first licensed private cord blood banking company in the United States, will now have its own processing and cryogenic storage lab strategically located within one mile of the nation's 5th busiest airport, which will reduce our shipping costs significantly," Schissler added. "That combined with Nevada's desire to diversify its business climate, incentives and lower costs of doing business, along with a much friendlier tax structure, are all keys in our decision focused on success and long term cost reduction for CBAI."
"The lab will also allow Cord Blood America to seek research grants for stem cell research," Mr. Schissler said. "Having this lab significantly enhances the Company's future capabilities as it will enhance our scientific expertise supporting future research and product development."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 email@example.com
|SOURCE Cord Blood America, Inc.|
Copyright©2009 PR Newswire.
All rights reserved